Highlights Pfizer Inc. Sao Paulo

Equities

Market Closed - Sao Paulo Other stock markets 16:05:00 2024-06-25 EDT			5-day change	1st Jan Change
38.24 ^BRL	-0.08%		+2.60%	+10.27%

06-25	CVRx, Inc. Announces Appointment of Robert Allen John as Chief Revenue Officer, Effective June 27, 2024	CI
06-24	US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	RE

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	06-24	RE
Sarepta surges as investors cheer expanded use of gene therapy	06-21	RE
Sarepta surges as investors cheer expanded use of gene therapy	06-21	RE
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...	06-18
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday	06-18	MT
Pfizer Sued by Kansas Over Covid-19 Vaccine	06-18	MT
US FDA approves Merck's pneumococcal vaccine for adults	06-17	RE
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit	06-17	RE
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug	06-17	RE
Pfizer: improved overall survival in myeloma	06-14	CF
Pfizer's Phase 2 MagnetisMM-3 Study of ELREXFIO Shows Median Overall Survival of Over 2 Years	06-14	MT
Pfizer Inc. Announces Detailed Overall Survival Results from the Phase 2 MagnetisMM-3 Study of ELREXFIO	06-14	CI
Health Care Flat on Mixed Drug Developments - Health Care Roundup	06-13	DJ
Global markets live: Shell, Broadcom, Apple, Sony, Apple...	06-13
Pfizer : share price down, Duchenne clinical trial failure	06-13	CF
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	06-13	MT
Pfizer: presents results of treatment for DMD	06-13	CF
Pfizer Prospective Treatment for Duchenne Muscular Dystrophy Fails to Meet Goals	06-12	MT
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints	06-12	DJ
Pfizer's gene therapy for a muscle-wasting disorder misses main goal of late-stage study	06-12	RE

No results for this search

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs